New Risk • Apr 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$11.2m market cap, or US$7.99m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Mar 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$13.1m market cap, or US$9.32m). Announcement • Mar 17
Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,363,637
Price\Range: AUD 0.55
Transaction Features: Subsequent Direct Listing Announcement • Feb 11
Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million. Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 21,276,596
Price\Range: AUD 0.47
Transaction Features: Subsequent Direct Listing Announcement • Jan 20
Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million. Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,363,637
Price\Range: AUD 0.55
Transaction Features: Subsequent Direct Listing Announcement • Sep 15
Cambium Bio Limited, Annual General Meeting, Oct 16, 2025 Cambium Bio Limited, Annual General Meeting, Oct 16, 2025. Location: level 16, 101 miller street, north sydney, nsw 2060 Australia Announcement • Jul 30
Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million. Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,627,451
Price\Range: AUD 0.4637
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,828,266
Price\Range: AUD 0.4637
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 114,950
Price\Range: AUD 0.4637
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 114,948
Price\Range: AUD 0.4637
Transaction Features: Subsequent Direct Listing Announcement • Mar 07
Cambium Bio Limited Announces the Appointment of Li-Chien Chiu as Board of Director 07 March 2025, Cambium Bio Limited announced the appointment of Mr. Li-Chien Chiu to its Board of Directors, effective immediately. Mr. Chiu is the Chairman of Hocheng Corporation. He brings extensive corporate leadership experience to Cambium Bio, having led Hocheng Corporation since 2003. Following Cambium Bio's recent capital raising, Mr. Chiu holds 800,357 shares, representing a 4.38% stake in the Company. Mr. Chiu brings over 35 years of corporate leadership experience across multiple industries. His career includes senior roles at Hostan Corporation (Vice President, 1998- 2003), Hocheng Corporation (Marketing Department Manager, 1996-1998), Sanquan Construction (Executive Director, 1993-1996), Hocheng Corporation North America Branch (Vice President, 1990-1993), and Hanyang Construction (Construction Site Director, 1988-1990). He holds a degree from the University of San Francisco, which he obtained in 1987. The appointment of Mr. Chiu further strengthens Cambium Bio's Board, which has recently been enhanced with the additions of Dr. ChiTai Chang in October 2024 and Clinical A/Prof Chandra Bala in November 2024. Together with existing Board members, this expanded leadership team possesses the diverse expertise necessary to guide Cambium Bio through its next phase of growth and clinical development. New Risk • Feb 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (AU$6.18m market cap, or US$3.92m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Announcement • Dec 05
Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million. Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,349,385
Price\Range: AUD 0.4637
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,012,490
Price\Range: AUD 0.4637
Transaction Features: Subsequent Direct Listing Announcement • Nov 22
Cambium Bio Limited Announces Board Changes Cambium Bio Limited announced changes to its Board of Directors. Clinical A/Prof Chandra Bala, MBBS, PhD, will join Cambium's Board effective 22 November 2024. A world-renowned ophthalmologist, A/Prof Bala brings extensive expertise in cataract, cornea, and refractive surgery. His distinguished career spans academia, research, and clinical practice, with numerous publications in international peer- reviewed journals and significant involvement in Phase 2 to 4 ophthalmic clinical trials. As senior partner at PersonalEyes, a leading ophthalmic group operating 12 clinics across Australia, and in his role as a cornea surgeon at Macquarie University Hospital, A/Prof Bala demonstrates a commitment to excellence in patient care. His dedication to advancing ophthalmic medicine through translational research, teaching, and community service aligns perfectly with Cambium's mission to innovate in the field of regenerative medicine. Prof. Graham Vesey will retire from the Board of Directors effective as of 22 November 2024. The Board would like to thank Dr. Vesey for his contribution to the Company since its founding in 2007 and subsequent listing on the ASX in 2013. New Risk • Nov 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (AU$4.89m market cap, or US$3.22m). Announcement • Oct 10
Cambium Bio Limited Appoint Board of Directors Cambium Bio Limited announced two key appointments to strengthen its scientific and leadership teams. Appointment of Dr. Louis Tong to Scientific Advisory Board. Dr. Louis Tong, a distinguished expert in ocular immunology and dry eye disease, has been appointed to Cambium Bio's Scientific Advisory Board. Dr. Tong is a Senior Consultant at the Singapore National Eye Centre, specializing in Corneal & External Eye Disease, and an Adjunct Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore. He is an internationally renowned clinician-scientist with over two decades of experience in ophthalmology, particularly in the areas of dry eye research and treatment development. He has authored more than 150 peer-reviewed publications and holds several patents in ophthalmic therapies. His wealth of expertise in clinical research will be instrumental in guiding Cambium Bio's ongoing development of novel dry eye disease therapeutics. Appointment of Dr. ChiTai Chang to Board of Directors. Dr. ChiTai Chang has been appointed to Cambium Bio's Board of Directors as a representative of Orient EuroPharma (Cyntec Co. Ltd.). Dr. Chang brings extensive experience in the pharmaceutical industry, with a strong background in strategic business development, commercialization of innovative products, and building partnerships in the healthcare sector. He has held senior leadership roles at multiple biotechnology firms where he successfully oversaw several drug development programs from early-stage research to regulatory approvals. Dr. Chang is currently the Chief Strategy Officer at Orient EuroPharma and holds a PhD in Chemistry from the University of Pittsburgh. Dr. Chang's proven track record in steering clinical programs to successful market entry will be invaluable as Cambium Bio progresses towards its goal of achieving FDA BLA approval for its lead candidate, Elate Ocular®, in dry eye disease. These appointments reflect Cambium Bio's ongoing commitment to enhancing its leadership capabilities and scientific acumen, ensuring the company remains at the forefront of ophthalmic innovation. Announcement • Oct 03
Cambium Bio Limited, Annual General Meeting, Nov 26, 2024 Cambium Bio Limited, Annual General Meeting, Nov 26, 2024. Board Change • Apr 08
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 